ArticleFrontiers in pharmacology2017

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer.

Esse I H Akpo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.